Abstract
Background To understand how the population immunity evolved over time and possible susceptibility of the Sri Lankan population to emerging SARS-CoV-2 variants, we proceeded to evaluate the changes in antibody positivity rates to omicron variants BA.2.75 and XBB.1.5 and for selected sarbecoviruses.
Methods The haemagglutination test (HAT) was carried out to determine the presence of antibodies against the RBD of the SARS-CoV-2 omicron variants XBB.1.5 and BA.2.75 and the RBD of the Sabecoviruses RaTG13, WIV1, Khosta-2 and SARS-CoV-1, in individuals aged 5 to 80 years of age in years 2020 (n=381), 2022 (n=432) and 2023 (n=382).
Results The highest positivity rates for BA.2.75, RaTG13, WIV1, Khosta-2 and SARS-CoV-1 were seen in 2022, with positivity rates significantly declining to many of the viruses except XBB.1.5 and Khosta-2 by 2023. The positivity rates for Khosta-2 (p<0.001) and WIVI (p<0.001) were significantly lower in children <14 years age, but not for XBB.1.5, BA.2.75 and RaTG13. Children <14 years who were SARS-CoV-2 unvaccinated had the lowest positivity rates for all tested viruses except BA.2.75. <20% of individuals in all age groups had antibody titres equivalent to 1:80, which correspond to neutralising antibody titres by 2023.
Conclusions Population immunity to omicron SARS-CoV-2 variants and selected sarbecoviruses had significantly declined in Colombo, Sri Lanka by 2023. Therefore, although T cells might still offer some protection against severe disease, immunizing vulnerable individuals in the community with protective vaccine designs, might be important to consider at this stage.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
We are grateful to the NIH, USA (grant number 5U01AI151788-02), UK Medical Research Council and the Chinese Academy of Medical Sciences (CAMS) Innovation Fund for Medical Science (CIFMS), China (grant no. 2018-I2M-2-002).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethics review committee, University of Sri Jayewardenepura
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
↵# co-first authors
